HIV persists in the brain and the spinal cord of HIV infected individuals, although there is successful viral suppression in the immune system. These individuals hence exhibit cognitive decline.
HIV-positive patients are living longer, healthier lives thanks to combination antiretroviral therapy (cART), which prevents the virus from replicating and infecting additional cells. However, HIV's ability to persist in the body despite ongoing cART treatment remains a major obstacle to curing patients. Now, clinical trial results published in the Journal of Clinical Investigation show that HIV can be detected in the central nervous system of patients undergoing long-term cART, and its presence is linked to poor performance on cognitive tests.
Combination Therapy Found Safe & Effective in Prostate Cancer
Targeted treatment combinations offers potential options for men with progressive prostate cancer
Advertisement
‘HIV infected individuals on long-term combination retroviral therapy perform poorly on a series of cognitive tests despite successful viral suppression in the immune system.’
Read More..
Tweet it Now
Read More..
While it was known that cART cannot completely prevent HIV-associated neurological dysfunction, Serena Spudich (Yale University School of Medicine) and colleagues' study appears to be the first to detect the virus in the cerebrospinal fluid (CSF) of patients on long-term cART. Their discovery indicates that HIV can persist in the brain and spinal cord despite years of successful viral suppression. Importantly, Spudich et al. linked the presence of HIV in CSF with poorer performance on a series of cognitive tests, concluding that the brain and spinal cord remain vulnerable to the virus even when the immune system is spared.
In the accompanying commentary, David Clifford explains how Spudich et al.'s findings highlight the need to address viral mechanisms of cognitive decline in cART-treated patients.
Source: Eurekalert
Source: Eurekalert
Drug-Screening Tool Revealed Cancer-killing Combination Therapy
Method IDs which targeted therapies, inadequate on their own, can be paired up to kill non-responsive cancers
Advertisement
 Tumors in Pancreatic Cancer Could Shrink From CD40 Combination TherapyA new combination of immunotherapy and chemotherapy for pancreatic cancer caused tumors to shrink in the majority of evaluable patients. | Advertisement
|
Novel Combination Therapy Can Help Promote Wound Healing
Novel combination therapy can significantly improve wound healing by cutting the healing time into half when compared to control treatments.
Advertisement
Recommended Readings
Latest AIDS/HIV News
Though monkeypox can affect anyone, CDC research states that approximately 40% of people diagnosed with monkeypox in the US also test positive for HIV.
The Phase 1 trial for a preventive HIV vaccine candidate has initiated enrollment in both the United States and South Africa.
In the United States, African American women make up only 26% of female PrEP users, yet they account for 57% of new infections among women.
Scientists have made a groundbreaking discovery in the fight against HIV/AIDS with the successful resolution of the enigmatic immune-evading HIV protein complex.
Tailored quit-smoking programs are designed to address the risks associated with comorbidity in individuals living with HIV.